Forefront Analytics’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

Forefront Analytics’s Portfolio ORTX Stock Details ORTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-14,183	Closed	-$110K	–	71
2023 Q3	$110K	Buy	+14,183	New	+$76.8K	0.06%	53
2023 Q2	–	Sell	-14,654	Closed	-$78.7K	–	78
2023 Q1	$78.7K	Sell	14,654 -1,835	-11%	-$9.98K	0.04%	64
2022 Q4	$61.2K	Buy	16,489 +6,485	+65%	+$28.7K	0.03%	66
2022 Q3	$54K	Buy	10,004 +740	+8%	+$4.12K	0.03%	63
2022 Q2	$58K	Sell	9,264 -710	-7%	-$4.01K	0.03%	61
2022 Q1	$72K	Buy	9,974 +4,717	+90%	+$46.2K	0.03%	65
2021 Q4	$70K	Buy	5,257 +150	+3%	+$2.48K	0.02%	60
2021 Q3	$118K	Buy	5,107 +3,378	+195%	+$100K	0.04%	58
2021 Q2	$75K	Buy	1,729 +118	+7%	+$6.57K	0.03%	64
2021 Q1	$118K	Sell	1,611 -1,598	-50%	-$114K	0.05%	61
2020 Q4	$139K	Buy	3,209 +172	+6%	+$7.7K	0.06%	56
2020 Q3	$123K	Buy	3,037 +1,124	+59%	+$58.1K	0.06%	52
2020 Q2	$115K	Buy	+1,913	New	+$175K	0.07%	51

Other funds holding ORTX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Forefront Analytics's ORTX Position: Q4 2023 in Review

Forefront Analytics sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q4 2023, closing a stake of 14,183 shares — an estimated $110K sold.

Forefront Analytics first reported a position in ORTX in Q2 2020 and held it in 13 quarters. The position peaked at $139K in Q4 2020. 47 funds tracked by Wall St. Rank hold ORTX as of Q4 2023.

Forefront Analytics reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q4 2023 after selling out during the quarter.
Forefront Analytics sold 14,183 Orchard Therapeutics plc American Depositary Shares shares in Q4 2023, an estimated $110K.
Forefront Analytics first reported a position in Orchard Therapeutics plc American Depositary Shares in Q2 2020 and held it in 13 quarters.
Forefront Analytics's Orchard Therapeutics plc American Depositary Shares position peaked at $139K in Q4 2020.
47 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q4 2023.

Based on Forefront Analytics's 13F filing for Q4 2023, filed 14 Feb 2024.